KaydedilenlerDerginizi ekleyin

Dergiler / Neurological sciences and neurophysiology (Online) / 2021 / Cilt: 38 - Sayı: 2

Anti‑Myelin Oligodendrocyte Glycoprotein‑Associated Disease with Recurrent Tumefactive Demyelinating Lesions

Hüseyin Nezih ÖZDEMİR
Ahmet GÖKÇAY
Figen GÖKÇAY
Cenk ERASLAN
Sayfa
143–145
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

ÖZDEMİR, H. N., GÖKÇAY, A., GÖKÇAY, F., ERASLAN, C. (2022). Anti‑Myelin Oligodendrocyte Glycoprotein‑Associated Disease with Recurrent Tumefactive Demyelinating Lesions. Neurological sciences and neurophysiology (Online), Cilt: 38 - Sayı: 2, 143–145. https://ajindex.com/articles/584296

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89‑102
  2. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca‑Fernandez A, et al. Clinical presentation and prognosis in MOG‑antibody disease: A UK study. Brain 2017;140:3128‑38
  3. Ataka T, Kimura N, Matsubara E. A case of myelin oligodendrocyte glycoprotein‑antibody‑associated disease presenting with tumefactive demyelinating lesion. Mult Scler Relat Disord 2020;43:102191
  4. Katsuse K, Kurihara M, Sugiyama Y, Kodama S, Takahashi M, Momose T, et al. Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti‑MOG antibody associated disease. Mult Scler Relat Disord 2019;27:91‑4
  5. Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord 2017;14:72‑9.